Pharmalot… Pharmalittle… Coffee and headlines are served…
Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where the shortest of short people has left for the local schoolhouse and the official mascots are happily snoozing underfoot. As for us, yes, we are quaffing our ritual cups of stimulation and, of course, we invite you to join us. Meanwhile, we have assembled a few items of interest to help you along. Hope your day goes well and drop us a line if you hear something juicy…
The latest analysis of drug prices shows companies have often boosted prices beyond the inflation rate to drive their revenue, even when demand is flagging; If biotech industry leaders agree on anything, it’s that Turing Pharmaceuticals chief executive Martin Shkreli has made life difficult for all of them; The largest US health insurers want doctors to stick with standard diabetes treatments instead of a new drug called Jardiance from Eli Lilly; and The deadline for MannKind, which makes the Afrezza inhaled insulin, to settle debt totaling $32 million passed five days ago, but the company has said nothing publicly, which means debtholders were probably paid with cash, its least attractive option.